Form 4: ResMed Chairman Emeritus Peter Farrell Sells Shares

ResMed Chairman Emeritus Peter C. Farrell sold 2,000 shares of common stock at $225 per share via a 10b5-1 trading plan.

Summary

• Peter C. Farrell, Chairman Emeritus of ResMed Inc., executed a sale of 2,000 shares of common stock.
• The transaction occurred on April 1, 2026, at a price of $225 per share.
• Following this transaction, Farrell retains beneficial ownership of 60,773 shares of ResMed common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing, automated trading plan.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though this was a pre-scheduled sale.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by key insiders.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives and board members to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the total outstanding shares.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

ResMed, RMD, Insider Trading, Form 4, Peter Farrell, Stock Sale